Preimplantation genetic diagnosis (PGD) is the inspection of an embryo in vitro in order to eliminate a genetic condition in case a high risk of that condition is known. PGD is an evolving technique that provides a practical alternative to prenatal diagnosis and termination of pregnancy for couples who are at substantial risk of transmitting a serious genetic disorder to their offspring.
According to a new market report published by Transparency Market Research “Preimplantation Genetic Diagnosis Market – Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023”, the PGD market in Asia was valued at US$ 16.0 Mn in 2014 and is projected to expand at a CAGR of 6.8% from 2015 to 2023 to reach US$ 28.8 Mn by 2023.
The usage of preimplantation genetic diagnosis (PGD) to screen genetic diseases and embryos for aneuploidy is increasing considerably. PGD benefits people at the risk of passing on a particular genetic disease to the next generation. PGD tests can be done for almost hundred different genetic diseases or conditions. The growing applications of PGD are expected to propel the Asia preimplantation genetic diagnosis market in the years to come. Over the past few years, there has been an increase in the number of people suffering from genetic diseases. The increase in patient awareness about various PGD techniques and the advancements in PGD techniques are expected to benefit the Asia preimplantation genetic diagnosis market in the next few years.
PGD is 98% accurate in determining various genetic abnormalities. The accuracy rate of PGD techniques makes it a popular choice among many people to treat their genetic diseases. The Asia preimplantation genetic diagnosis market is expected to progress at a 6.80% CAGR during the period between 2015 and 2023. The market stood at US$16.0 mn in 2014 and is expected to reach US$28.8 mn by 2023 owing to factors such as the increasing occurrence of various diseases such as hereditary breast cancer, asthma, cancer, and congenital heart diseases.
Aneuploidy Screening Segment to Dominate Asia PGD Market
The Asia preimplantation genetic diagnosis market is segmented on the basis of geography, end-user, and test type. By test type, the Asia preimplantation genetic diagnosis market is classified into chromosomal aberrations, aneuploidy screening, gender selection, single gene disorder, HLA typing, and X-linked diseases. In 2014, the aneuploidy screening segment held a dominant share of 35% in the Asia preimplantation genetic diagnosis market. By end user, the Asia preimplantation genetic diagnosis market is classified into health care facilities (including diagnostic centers, hospitals, and healthcare facilities), fertility clinics, and research centers.
The introduction of new PGD technologies is predicted to benefit the Asia preimplantation genetic diagnosis market. Leading players in the Asia preimplantation genetic diagnosis market are focusing on improving the existing techniques of PGD as well as introducing new ones. As per the Malaysian Medical Council (MMC) guidelines, it is prohibited to create designer babies using PGD. More and more Asians are currently heading to nations such as Thailand for availing medical procedures that allow them to choose the gender of their babies.
Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9989
Untapped Opportunities to be Responsible for Growth of Asia PGD Market
By geography, the Asia preimplantation genetic diagnosis market is divided into Eastern Asia, South Eastern Asia, Central Asia, and Western Asia. Southern Asia includes countries such as Sri Lanka, India, and Rest of Southern Asia. South Eastern Asia constitutes countries such as the Philippines, Thailand, Malaysia, and Rest of South Eastern Asia. Eastern Asia constitutes countries including South Korea, Japan, China, and Rest of Eastern Asia. The presence of many untapped opportunities is expected to propel the Asia preimplantation genetic diagnosis market in the next few years.
Some of the prominent players operating in the Asia preimplantation genetic diagnosis market are Genesis Genetics (U.S.), Illumina, Inc. (U.S.), Natera, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Reproductive Genetics Innovations LLC (U.S.), Genea Limited (Australia), Laboratory Corporation of America Holdings (U.S.), PerkinElmer, Inc.(U.S.), and Reprogenetics (U.S.)
Mr. Sudip S
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453
Email:Â [email protected]
Rejected Everywhere For A Merchant Account? We have a solution! Low – High-Risk Merchant Account Specialists. Unlimited Processing at 0%. No Contracts. No Shut Downs. No Set-Up & Application Fees. FREE Gateway Set-Up – Secured Transactions.
Open a New Merchant Account Here Now – OPEN MERCHANT ACCOUNT. PAYMENTS – PERFECTED.